Home

Nima Farzan

CIK 1808296 · CHIEF EXECUTIVE OFFICER · last filed 2026-06-08

Nima Farzan is a CHIEF EXECUTIVE OFFICER who has filed 14 SEC Form 4 insider transactions across 2 companies since 2020. The most recent filing shows the insider sold $28.2K of KROS on Jun 8, 2026. Across all open-market trades the lifetime net is −$28.2K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $98.4K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$98.4K

Companies

2

Total Filings

14

Lifetime Open-Market Net

-$28.2K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KROS Director 9,767 $10.07 $98.4K -$28.2K 8 2026-06-08
Kinnate Biopharma Inc. (KNTE) Delisted Chief Executive Officer — $2.65 — $0 4 2023-02-15

Recent Filings

14 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-08 KROS Sell (S) −2,625 -$28.2K EDGAR
2026-06-05 KROS Grant (A) +7,142 $0 EDGAR
2026-06-04 KROS Notice (144) −2,625 -$28.0K EDGAR
2025-06-06 KROS Grant (A) +5,250 $0 EDGAR
2024-06-03 KROS Grant (A) — $0 EDGAR
2024-04-05 — Disp (D) −2,186 $0
2023-06-08 KROS Grant (A) — $0 EDGAR
2023-02-15 Kinnate Biopharma Inc. (KNTE) Delisted Grant (A) — $0 EDGAR
2023-02-14 Kinnate Biopharma Inc. (KNTE) Delisted Grant (A) — $0 EDGAR
2022-06-03 KROS Grant (A) — $0 EDGAR
Showing 1–10 of 14
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.